Clinical Trial Update: A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating dasatinib in patients with imatinib-resistant or -intolerant chronic myeloid leukemia has completed. The update summarizes the trial'…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Kanto CML Study Group | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED